

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/525,015
Confirmation Number	5025
Filing Date	February 17, 2005
First Named Inventor	Noboru YAMAJI
Art Unit	1654
Examiner Name	Andrew D. KOSAR
Attorney Docket Number	Q86324

U.S. PATENTS

Examiner Initials*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1					

U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initials*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1					

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
	1							

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	T ⁵
	1	AIGNER et al., Anabolic and Catabolic Gene Expression Pattern Analysis in Normal Versus Osteoarthritic Cartilage Using Complementary DNA-Array Technology, Arthritis and Rheumatism, Dec. 2001, Vol. 44, No. 12, pp. 2777-2789.	N
	2	DAMJANOVSKI et al., Multiple state-dependent roles for histone deacetylases during amphibian embryogenesis: Implications for the involvement of extracellular matrix remodeling, International Jour. Dev. Biology, 2000, Vol. 44, No. 7, pp 769-776.	N
	3	KIM et al., Aplidin, an inhibitor of histone deacetylase, prevents H-ras-induced invasive phenotype, Cancer Letters, 2000, Vol. 157, No. 1, pp. 23-30.	N
	4	HUANG et al., Nitric oxide (NO), methylation and TIMP-1 expression in BL6 melanoma cells transfected with MHC class I genes, Clinical and Experimental Metastasis, 2000, Vol. 18, No. 4, pp. 329-335.	N
	5	GORE et al., Impact of Prolonged Infusions of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia, Clinical Cancer Research, Apr. 2002, Vol. 8, No. 4, pp. 963-970.	N
	6	EMILIANI et al., Characterization of a human RPD3 ortholog, HDAC3, Proc. Natl. Acad. Sci. USA, 1998, Vol. 95, No. 6, pp. 2795-2800.	N
	7	Japanese Office Action dated April 2, 2008	Y

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.